🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our latest work: “liquid biopsy epigenomic profiling for cancer subtyping”, JUST IN Nature Medicine nature.com/articles/s4159…

The erudite Oliver Sartor w/ the long awaited #PSMAfore data comparing #PSMALu vs abi/enza for met #prostatecancer pre-chemo. Improved rPFS & trending toward OS benefit despite planned x-over. Dry mouth most bothersome — less AEs overall for Lu than for ARTA. #ESMO23 OncoAlert

⁦Christopher Sweeney, MBBS⁩ giving an excellent discussion on placing PSMAFore data in context. ⁦Thomas Hope⁩ ⁦Alan Tan⁩ ⁦Toni Choueiri, MD⁩ ⁦@morr316⁩ #ESMO2023

Noninvasive detection of NEPC by targeted cfDNA methylation Cancer Discovery co-led by Francesca Demichelis and her lab Università di Trento. Congrats to first author Gian Marco Franceschini 🇺🇦 and thank you to many amazing collaborators PCF Science Dana-Farber Lank Center for Genitourinary Oncology #NEMO aacrjournals.org/cancerdiscover…

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

To my amazing brother-(in law): visionary scientist, incredible mentor, loving husband and father - ❤️❤️❤️ He’s lifted up so many. So fitting for a YIA to be dedicated to him and moving to see such an outpouring of support - Please donate if you can …

What an incredible way to spend last Saturday - surrounded by the brightest minds in the field and more importantly, the brightest lights in my life. Thank you all for coming out and attending the #FengSymposium! I am so grateful for you all 🙏🏼

Masterful discussion by Wenxin (Vincent) Xu of the biomarker data presented, including the KIM-1 data to which he has personally had very important contributions. ASCO #ASCO24

Standing room only for #ESMO24 prostate session, Misha Beltran excellent discussions on DLL3 targeting in neuroendocrine prostate cancer and Neeraj Agarwal, MD, FASCO on T-cell engagers

Terrific overview of BiTEs in #prostatecancer at #ESMO24 by Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute. #PSMA, #STEAP1, #DLL3 & other targets being exploited with varying levels of success. BEAUTIFUL comprehensive tables included in his talk that give immediate perspective of the status of

Huge congrats to Andrea Apolo, M.D. Guru P. Sonpavde, MD Jonathan Rosenberg MD William Y. Kim Stephanie Berg & the Alliance for Clinical Trials in Oncology team on a terrific ESMO - Eur. Oncology presentation & a concomitant NEJM paper! A very exciting #ESMO24 indeed!

Our poster #ESMO2024 (1646P): ADT + Doce + Nivo in pts with DDR-proficient & immune-cold mHSPC did not meet PSA endpoint; 3/20 pts with durable responses; post-ADT baseline CTCs indicate persistent AR signaling as resistance mechanism. Biomarker ➕ cohorts results to follow.

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

PSMAfore published The Lancet today. Proud to have contributed to this impactful study. 50-day 🔗 to full-article: authors.elsevier.com/c/1jmkBV-4XOuQK

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024

It was such an honor giving the Felix Feng Lecture at the #pcfretreat24 on Friendship and Science. Thank you Felix for all your contributions to the field and for being an amazing friend. The love for you in the room was just palpable PCF Science

Honored to be among 12 outstanding oncology leaders on the ASCO Election ballot! Make your voice heard in shaping our society's future - vote now at asco.org/election. Every ballot strengthens our mission to advance cancer care.

Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in European Urology Oncology: sciencedirect.com/science/articl…

We are happy to share our work led by Aram Lyu and Zenghua Fan on why prostate cancer is so resistant to immunotherapy. nature.com/articles/s4158…

Tonight we sit with the cherished memories of a truly unforgettable individual who changed the lives of so many fighting cancer. Tomorrow we stand and get back to the fight against the terrible disease that took one of our best, brightest, and kindest. Love you forever, Felix.